BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12063571)

  • 1. CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo.
    Wick W; Stock J; Seyfried J; Baumgart J; Wüllner U; Weller M
    Int J Oncol; 2002 Jul; 21(1):213-20. PubMed ID: 12063571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2.
    Reber U; Wüllner U; Trepel M; Baumgart J; Seyfried J; Klockgether T; Dichgans J; Weller M
    Biochem Pharmacol; 1998 Feb; 55(3):349-59. PubMed ID: 9484802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-buthionine sulfoximine potentiates the antitumor effect of 4-hydroperoxycyclophosphamide when administered locally in a rat glioma model.
    Sipos EP; Witham TF; Ratan R; Burger PC; Baraban J; Li KW; Piantadosi S; Brem H
    Neurosurgery; 2001 Feb; 48(2):392-400. PubMed ID: 11220384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming tumor necrosis factor-alpha resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-alpha. Role of tumor necrosis factor-alpha mRNA down-regulation in tumor cell sensitization.
    Mizutani Y; Yoshida O
    Cancer; 1994 Feb; 73(3):730-7. PubMed ID: 8299097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells.
    Roth W; Wagenknecht B; Dichgans J; Weller M
    J Neuroimmunol; 1998 Jul; 87(1-2):121-9. PubMed ID: 9670853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest.
    Roth W; Wagenknecht B; Grimmel C; Dichgans J; Weller M
    Br J Cancer; 1998; 77(3):404-11. PubMed ID: 9472635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells.
    Allalunis-Turner MJ; Day RS; McKean JD; Petruk KC; Allen PB; Aronyk KE; Weir BK; Huyser-Wierenga D; Fulton DS; Urtasun RC
    J Neurooncol; 1991 Oct; 11(2):157-64. PubMed ID: 1744683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD95 ligand: lethal weapon against malignant glioma?
    Weller M; Kleihues P; Dichgans J; Ohgaki H
    Brain Pathol; 1998 Apr; 8(2):285-93. PubMed ID: 9546287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
    Lanvers-Kaminsky C; Bremer A; Dirksen U; Jürgens H; Boos J
    Anticancer Drugs; 2006 Jul; 17(6):657-62. PubMed ID: 16917211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
    Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP
    J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.
    Friedman HS; Colvin OM; Griffith OW; Lippitz B; Elion GB; Schold SC; Hilton J; Bigner DD
    J Natl Cancer Inst; 1989 Apr; 81(7):524-7. PubMed ID: 2921776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma.
    Palomares T; Bilbao P; del Olmo M; Castro B; Calle Y; Alonso-Varona A
    Melanoma Res; 1999 Jun; 9(3):233-42. PubMed ID: 10465578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioma apoptosis induced by macrophages involves both death receptor-dependent and independent pathways.
    Chen GG; Chak EC; Chun YS; Lam IK; Sin FL; Leung BC; Ng HK; Poon WS
    J Lab Clin Med; 2003 Mar; 141(3):190-9. PubMed ID: 12624600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
    Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
    Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy with photofrin in combination with Buthionine Sulfoximine (BSO) of human glioma in the nude rat.
    Jiang F; Robin AM; Katakowski M; Tong L; Espiritu M; Singh G; Chopp M
    Lasers Med Sci; 2003; 18(3):128-33. PubMed ID: 14505195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additivity, antagonism, and synergy in arsenic trioxide-induced growth inhibition of C6 glioma cells: effects of genistein, quercetin and buthionine-sulfoximine.
    Klauser E; Gülden M; Maser E; Seibert S; Seibert H
    Food Chem Toxicol; 2014 May; 67():212-21. PubMed ID: 24632069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
    Winter S; Weller M
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1374-82. PubMed ID: 9732400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
    Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
    Pigment Cell Res; 1997 Aug; 10(4):236-49. PubMed ID: 9263331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of rats bearing advanced intracerebral F 98 tumors after glutathione depletion and microbeam radiation therapy: conclusions from a pilot project.
    Schültke E; Bräuer-Krisch E; Blattmann H; Requardt H; Laissue JA; Hildebrandt G
    Radiat Oncol; 2018 May; 13(1):89. PubMed ID: 29747666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model.
    Neuwelt EA; Pagel MA; Hasler BP; Deloughery TG; Muldoon LL
    Cancer Res; 2001 Nov; 61(21):7868-74. PubMed ID: 11691805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.